Development of an experimental influenza antiviral drug that may be more potent and could have a longer treatment window than existing drugs will receive support from the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR). The drug is being developed for use in treating patients hospitalized with influenza.
If development is successful and the drug receives US Food and Drug Administration approval, the drug could become the first specifically for this use and potentially the first in a new class of influenza antivirals.
$103.5 million contract with Janssen Pharma
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze